Detalles de la búsqueda
1.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 386(12): 1132-1142, 2022 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35179323
2.
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
BJU Int
; 133 Suppl 3: 57-67, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37986556
3.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(10): 1094-1108, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37714168
4.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36990608
5.
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
Oncologist
; 28(1): 59-71, 2023 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35881028
6.
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 398(10295): 131-142, 2021 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34246347
7.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
; 381(2): 121-131, 2019 07 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31157964
8.
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
BJU Int
; 128 Suppl 1: 18-26, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34622543
9.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Lancet
; 393(10189): 2404-2415, 2019 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31079938
10.
Clinical guidance for radioiodine refractory differentiated thyroid cancer.
Clin Endocrinol (Oxf)
; 88(4): 529-537, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29095527
11.
Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer.
BJU Int
; 131(2): 179-182, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36371671
12.
Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort.
J Geriatr Oncol
; 14(8): 101621, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37683368
13.
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
Eur Urol
; 83(4): 320-328, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35654659
14.
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Expert Rev Pharmacoecon Outcomes Res
; 23(2): 231-239, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36541133
15.
Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations.
JCO Oncol Pract
; 19(11): 973-980, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37327464
16.
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
Eur Urol
; 84(1): 109-116, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36707357
17.
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol
; 83(2): 145-151, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36272943
18.
Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer.
BJUI Compass
; 3(3): 205-213, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35492221
19.
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis.
Asia Pac J Clin Oncol
; 18(6): 642-649, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35098653
20.
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.
Eur Urol
; 82(3): 283-292, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35210132